A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Study of Domvanalimab and Zimberelimab Alone or in Combination with Chemotherapy in Patients with Upper Gastrointestinal Cancers (UGI)
Sponsor: Arcus Bioscience, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU1634
U.S. Govt. ID: NCT05329766
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to help Arcus Biosciences, Inc. (the Sponsor) understand whether study drugs domvanalimab (also called AB154) plus zimberelimab (also called AB122) are safe and effective when given together with and without standard-of-care chemotherapy (FOLFOX) to patients with the type of cancer you have. Domvanalimab and zimberelimab are considered as immunotherapy. This type of treatment works by blocking a protein (programmed death-ligand 1, or PD-L1) that can cause tumors to grow. By blocking this protein, the study drugs may cause your cancer to stop growing or shrink. These study drugs are investigational meaning they are not approved by the United States Food and Drug Administration (US FDA), or any other agencies like the US FDA, to treat your cancer.
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with an upper gastrointestinal cancer (UGI)? Yes No
Are you comfortable receiving the study drug through a vein? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162